Oral administration of a soluble 1-3, 1-6 beta-glucan during prophylactic survivin peptide vaccination diminishes growth of a B cell lymphoma in mice

Tools

Item Type:	Article
Title:	Oral administration of a soluble 1-3, 1-6 beta-glucan during prophylactic survivin peptide vaccination diminishes growth of a B cell lymphoma in mice
Creators Name:	Harnack, U., Eckert, K., Fichtner, I. and Pecher, G.
Abstract:	beta-glucans are biological response modifiers with activatory effects on macrophages, dendritic cells (DC), granulocytes and NK-cells. In this study, we investigated the effect of a soluble yeast-derived beta- (1-3), (1-6)-D-glucan on prophylactic peptide vaccination against the B cell lymphoma A20 in syngeneic Balb/c mice. We found that repeated immunizations with two MHC class I-restricted peptides derived from the tumor antigen survivin combined with oral co-administration of beta-glucan could significantly diminish intradermal tumor growth, whereas peptide vaccination alone failed to control tumor growth. beta-glucan as single agent induced only a weak but non-significant growth inhibitory effect. To determine whether the tumor inhibitory effect of the combined treatment was associated with the induction of a tumor specific immune response we quantified splenic DC and macrophages, analyzed the maturation of DC and measured the frequency of peptide-specific CD8(+) and CD4(+) T cells. Treated mice showed significantly increased numbers of splenic macrophages and mature DC compared to untreated tumor bearing mice. After restimulation with both peptides in vitro elevated levels of interferon (IFN)-gamma-secreting CD8(+) T cells were found in two of four tested mice following treatment and one of four mice showed a strong increase of interleukin (IL)-4-secreting CD4(+) T cells. Our data reveal a beneficial effect of beta- (1-3), (1-6)-D-glucan in tumor growth inhibition by tumor specific peptide vaccination which may rely on a function of the polymeric sugar as immunological adjuvant.
Keywords:	A20 Lymphoma, beta-Glucan, Survivin, Tumor Peptide Vaccination, Animals, Mice
Source:	International Immunopharmacology
ISSN:	1567-5769
Publisher:	Elsevier
Volume:	9
Number:	11
Page Range:	1298-1303
Date:	October 2009
Official Publication:	https://doi.org/10.1016/j.intimp.2009.07.013
PubMed:	View item in PubMed

Repository Staff Only: item control page